文献速递类风湿关节炎

接受Janus激酶抑制剂治疗的类风湿关节炎患者的癌症风险:一项丹麦全国登记-based队列研究

Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

在丹麦全国登记中纳入875例JAKi组和4247例bDMARD组RA患者,比较首次原发癌症风险。JAKi组粗发病率为14.4/1000人年,bDMARD组为12.9/1000人年;加权Cox模型HR为1.41(95%CI 0.76, 2.37),未达统计学显著。作者认为JAKi治疗与癌症风险无统计学显著增加,但不能排除临床重要的超额风险。

要点

  • JAKi组875例、bDMARD组4247例,首次原发癌症粗发病率分别为14.4和12.9/1000人年。
  • 加权Cox模型显示JAKi vs bDMARD的HR为1.41(95%CI 0.76, 2.37),未达统计学显著。
  • 作者指出多个风险估计值数值上升高,不能排除JAKi受体者临床重要的癌症超额风险。

核心结论

  • 在真实世界RA患者中,与接受bDMARDs者相比,JAKi治疗与首次原发癌症风险无统计学显著增加相关。
  • 但检测到多个数值上升的风险估计值,不能排除JAKi受体者临床重要的癌症超额风险。

研究设计与样本

  • 采用丹麦全国登记进行的观察性队列研究。
  • 纳入2017年1月1日至2020年12月31日期间启动JAKi或bDMARDs治疗、年龄18岁以上、无既往癌症诊断的RA患者。
  • 随访首次原发癌症(除外非黑色素瘤皮肤癌),采用逆概率治疗加权(IPTW)校正组间协变量差异,并以加权原因别Cox模型计算癌症发病的风险比(HR)。

主要发现

  • 共识别JAKi组875例和bDMARD组4247例RA患者。
  • JAKi组贡献1315人年、19例癌症,bDMARD组贡献8597人年、111例癌症,相应粗发病率分别为每1000人年14.4和12.9。
  • 加权原因别Cox模型显示,JAKi组 vs bDMARD组首次原发癌症的HR为1.41(95%CI 0.76, 2.37)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We aimed to investigate the risk of first primary cancer in patients with RA treated with janus kinase inhibitors (JAKi) compared with those who received biologic DMARDs (bDMARDs) in a real-world setting. METHODS: We performed an observational cohort study using the nationwide registers in Denmark. Patients with RA aged 18+ years, without a previous cancer diagnosis, and who initiated treatment with JAKi or bDMARDs from 1 January 2017 to 31 December 2020 were followed for any cancer (except non-melanoma skin cancer). We applied inverse probability of treatment weighting (IPTW) to account for covariate differences between treatment groups. IPTW-generated weights were used with cause-specific Cox (CSC) models to calculate hazard ratios (HRs) for cancer incidence in JAKi-treated compared with bDMARD-treated patients with RA. RESULTS: We identified 875 and 4247 RA patients treated with JAKi and bDMARDs, respectively. The JAKi group contributed 1315 person years (PYRS) and 19 cancers, the bDMARD group contributed 8597 PYRS and 111 cancers, with corresponding crude incidence rates per 1000 PYRS of 14.4 and 12.9. Comparing the two groups using weighted CSC models, a HR of 1.41 (95% CI 0.76, 2.37, 95% CIs) was seen for JAKi- vs bDMARD-treated patients with RA. CONCLUSION: JAKi treatment in real-world patients with RA was not associated with a statistically significant increased risk of first primary cancer compared with those who received bDMARDs. However, several numerically increased risk estimates were detected, and a clinically important excess risk of cancer among JAKi recipients cannot be dismissed.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Westermann R, Cordtz RL, Duch K, et al. Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study. Rheumatology (Oxford). 2024. PMID: 37052534. doi:10.1093/rheumatology/kead163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。